ADC BIO is an innovative biotechnology company. Specialising in Antibody Drug Conjugates.
We’re developing new process technology. To speed, simplify and significantly lower the production costs of the latest generation of anticancer blockbuster ADC drugs.
TECHNOLOGY
TARGETING DISEASE.
WITH PRECISION.
ADC BIO’s proprietary Lock-Release technology is a fast, simple, cost efficient and robust system to guarantee ADCs of a consistently high quality and purity.
We’re nimble, flexible and focused on helping ADC drug developers bring the next generation of anticancer drugs to life.
We are pleased to announce that Global contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions (Sterling) has made a new strategic partnership with our Company. The partnership will see Sterling make a significant investment in the business with a view to acquiring ADC Biotechnology…
READ PRESS RELEASE
